1 Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Biomedical Center, SE-751 24, Uppsala, Sweden. doroteya.raykova@farmbio.uu.se.
2 Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Biomedical Center, SE-751 24, Uppsala, Sweden.
3 Atlas Antibodies AB, Bromma, Sweden.
4 Faculty of Medicine, University of Porto, Porto, Portugal.
5 Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal.
6 Department of Sciences, University Institute of Health Sciences (IUCS), CESPU, Gandra, Portugal.
7 Vi2, Department of Information Technology and SciLifeLab BioImage Informatics Facility, Uppsala University, Uppsala, Sweden.
8 Department of Immunology, Genetics and Pathology, Uppsala University, Rudbeck Laboratory, Uppsala, Sweden.
9 Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Biomedical Center, SE-751 24, Uppsala, Sweden. ola.soderberg@farmbio.uu.se.